De-simplifying single-tablet antiretroviral treatments for cost savings in France: From the patient perspectives to a 6-month follow-up on generics.
In developed countries, most people living with HIV/AIDS are treated with costly brand single-tablet regimens. Given the economic impact, French guidelines recommend using generic antiretroviral therapy when possible to decrease antiretroviral therapy costs. We aimed to study HIV-infected patients...
Main Authors: | Jean-Stephane Giraud, Melanie Doisne, Aurelie Chan Hew Wai, Catherine Majerholc, Erwan Fourn, Karine Sejean, Julie Trichereau, Brigitte Bonan, David Zucman |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0239704 |
Similar Items
-
COVID-19 Vaccine Hesitancy among French People Living with HIV
by: Alexandre Vallée, et al.
Published: (2021-03-01) -
Implementation of a remote oncology-monitoring program for cancer patients in outpatient care unit
by: Peyrilles Elodie, et al.
Published: (2017-03-01) -
Desimplification of Single Tablet Antiretroviral (ART) Regimens—A Practical Cost-Savings Strategy?
by: Hartmut Krentz PhD, et al.
Published: (2019-01-01) -
An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines
by: Alexandre Vallée, et al.
Published: (2021-08-01) -
Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohort.
by: Matthias Stoll, et al.
Published: (2011-01-01)